The world is facing a dire need for new antibiotics and vaccines, with drug-resistant infections claiming nearly 5 million lives annually. Basecamp Research, a company dedicated to exploring 'Beyond Known Biology', has developed a groundbreaking solution: EDEN, a powerful tool that combines antibiotic design and vaccine target prediction. By integrating EDEN with Claude, an AI workbench for life sciences research, scientists can now design potent antibiotics and rapidly prioritize vaccine targets in a matter of minutes.
EDEN's capabilities are truly remarkable. Trained on BaseData, the world's largest biological dataset, it has been used to document over a million species new to science, resulting in over 10 billion new genes. This vast amount of data allows EDEN to outperform other biological AI models, which are often limited to well-studied organisms. The model's performance is further enhanced by its diverse training, with samples collected from various locations, including thermal springs, deep-sea sediment, polar ice, and remote high-altitude plateaus.
In collaboration with the University of Pennsylvania, Basecamp Research demonstrated EDEN's effectiveness. 97% of the antibiotic peptides designed by EDEN were active against World Health Organisation (WHO) priority pathogens when tested in the lab. One candidate, EDEN-7, showed remarkable efficacy against multidrug-resistant Acinetobacter baumannii, a pathogen associated with hospital outbreaks worldwide, without the need for subsequent optimization or iterative engineering.
The impact of this technology is profound. By combining Claude's reasoning with EDEN's biological design capabilities, researchers can go straight from a target to a shortlist of high-performing antibiotic or vaccine candidates. This streamlined process can significantly reduce the time and resources required for antibiotic and vaccine development, potentially saving countless lives.
Furthermore, EDEN's vaccine design model identifies which proteins are most likely to trigger a protective immune response, outperforming comparable genomic foundation models. By integrating it into Claude, researchers can describe a problem in plain language and have Claude run a prioritization workflow against the pathogen's genetic sequence, reducing several weeks of research per pathogen into a single conversation.
The collaboration between Basecamp Research and Anthropic, NVIDIA, PacBio, and Ultima Genomics to scale BaseData 100-fold over the next two years through the Trillion Gene Atlas is a significant development. This partnership aims to generate genomic data at the trillion-gene scale for AI-driven drug discovery, further enhancing EDEN's capabilities and accelerating therapeutic development.
In conclusion, the integration of EDEN with Claude represents a significant advancement in antibiotic and vaccine design. By harnessing the power of AI and vast biological datasets, researchers can now tackle some of the most pressing public health challenges more efficiently. This collaboration between academia and industry is a crucial step towards addressing the antibiotic crisis and the need for new vaccines, ultimately improving global health outcomes.
